Curis saw no growth in patent filings and highest growth of 3.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 3.99%. GlobalData’s DataBook provides a comprehensive analysis of Curis‘s patent filings and grants. Buy the databook here.
Curis has been focused on protecting inventions in Japan(JP) with three publications in Q2 2024
The Japan(JP) Patent Office dominates the patent filings and grants with nearly 20% filings and 33% grants. The United States(US), Japan(JP), Australia(AU), and Denmark(DK) patent Office are among the top ten patent offices where Curis is filings its patents. Among the top granted patent authorities, Curis has 33% of its grants in Japan(JP), 17% in Australia(AU) and 17% in European Patent Office(EPO).
Roche and Johnson & Johnson could be the strongest competitors for Curis
Patents related to rare diseases lead Curis's portfolio
Curis has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Intestinal cancer related patents lead Curis portfolio followed by adenocarcinoma, and carcinomas
Curis has highest number of patents in intestinal cancer followed by adenocarcinoma, carcinomas, breast cancer, and non-small cell lung cancer.
For comprehensive analysis of Curis's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.